{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:31:18Z","timestamp":1795095078806,"version":"4.10.2"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/inf.0000000000001072","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T13:55:18Z","timestamp":1454421318000},"page":"548-554","source":"Crossref","is-referenced-by-count":42,"title":["Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine"],"prefix":"10.1097","volume":"35","author":[{"given":"Shelly","family":"Senders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Bhuyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"York","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ginis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210202","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R4-19-20210202","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.vaccine.2013.09.055","article-title":"Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing.","volume":"32","author":"Azzari","year":"2014","journal-title":"Vaccine"},{"key":"R5-19-20210202","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"R6-19-20210202","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJMoa1005384","article-title":"Bacterial meningitis in the United States, 1998\u20132007.","volume":"364","author":"Thigpen","year":"2011","journal-title":"N Engl J Med"},{"key":"R7-19-20210202","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"R8-19-20210202","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"R10-19-20210202","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"R11-19-20210202","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase \u00bd trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R12-19-20210202","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R13-19-20210202","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"R14-19-20210202","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"R16-19-20210202","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"R18-19-20210202","first-page":"3","article-title":"Rationale for periodic reporting on the use of selected clinical preventive services to improve the health of infants, children, and adolescents\u2013United States.","volume":"63","author":"Yeung","year":"2014","journal-title":"MMWR Surveill Summ"},{"key":"R21-19-20210202","first-page":"289","article-title":"Serogroup B and C serum bactericidal assays.","volume":"66","author":"Borrow","year":"2001","journal-title":"Methods Mol Med"},{"key":"R22-19-20210202","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4161\/hv.34293","article-title":"The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease.","volume":"11","author":"Zlotnick","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R23-19-20210202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"R24-19-20210202","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1128\/CDLI.12.8.959-969.2005","article-title":"Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18.","volume":"12","author":"Dias","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"R25-19-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1128\/CDLI.10.1.108-115.2003","article-title":"Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.","volume":"10","author":"Opalka","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R26-19-20210202","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"R29-19-20210202","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity.","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"R30-19-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R33-19-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R34-19-20210202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"R35-19-20210202","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/603552","article-title":"Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.","volume":"49","author":"Lennon","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R39-19-20210202","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jadohealth.2013.05.009","article-title":"Missed opportunities for adolescent vaccination, 2006-2011.","volume":"53","author":"Wong","year":"2013","journal-title":"J Adolesc Health"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:10:05Z","timestamp":1620954605000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201605000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001072","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}